ELEVAI Labs Expands Portfolio and Restructures Subsidiaries

TipRanksMay 3 05:42

Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22.

Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies

BenzingaMay 3 00:06

Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset "EL-22" For The Treatment Of Obesity

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic fea

BenzingaMay 2 20:39

12 Consumer Staples Stocks Moving In Wednesday's After-Market Session

GainersElevai Labs (NASDAQ:ELAB) shares rose 22.7% to $0.8 during Wednesday's after-market session. The company's market cap stands at $13.8 million. Vintage Wine Estates (NASDAQ:VWE) shares rose 4.99

BenzingaMay 2 04:31

Elevai Labs Expands With Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development

GlobeNewswireMay 2 04:00

Elevai Labs Acquires Exclusive License To Two Myostatin Muscle Loss Prevention Assets, Announces Plan To Develop In Combination With GLP-1 Obesity Treatments

Elevai Labs Acquires Exclusive License To Two Myostatin Muscle Loss Prevention Assets, Announces Plan To Develop In Combination With GLP-1 Obesity Treatments

BenzingaMay 1 21:04